Paragon Bioservices has been awarded a contract from the National Institutes of Health (NIH) National Institute of Neurological Disorders and Stroke to design and establish a scale-up manufacturing process for the cGMP production of the recombinant human rhE-selectin protein.
The potential application of E-selectin in the clinic is based on the role that the compound plays in coordinating and responding to the immune system’s activation and resulting response.
NIH-NINDS research on E-selectin has been done by John Hallenbeck, MD, Chief of the NINDS Stroke Branch and a senior investigator in the Institute’s Clinical Investigations Section.
Dr. Hallenbeck’s laboratory is studying the cellular regulation of ischemic tolerance and inflammatory and immune mechanisms in the initiation and progression of stroke.
E-selectin control of molecular inflammation may help prevent thrombosis and hemorrhage and result in a new strategy for the prevention of recurrent strokes. Despite the current conventional use of antithrombotic drugs for the prevention, 10 percent of patients who experience any cerebral ischemic event will still go on to have a stroke within 90 days.
According to Paragon CEO Marco Chacon, PhD, “The Paragon team is happy to be a part of the process development and cGMP manufacturing of E-Selectin, a novel biologic of great clinical significance.”